ABIOMED INC's ticker is ABMD and the CUSIP is 003654100. A total of 494 filers reported holding ABIOMED INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 494,397 | $163,764,000 | 12.66% |
| Brown Capital Management | 1,378,805 | $456,715,000 | 4.54% |
| Biondo Investment Advisors, LLC | 76,033 | $25,185,000 | 4.44% |
| Ownership Capital B.V. | 752,402 | $249,226,000 | 3.29% |
| AMERICAN CAPITAL MANAGEMENT INC | 271,303 | $89,866,000 | 2.65% |
| Rhenman & Partners Asset Management AB | 68,000 | $22,524,000 | 2.22% |
| Bradley Mark J. | 9,375 | $3,106,000 | 2.21% |
| Chicago Capital, LLC | 153,764 | $50,933,000 | 2.19% |
| GENERATION INVESTMENT MANAGEMENT LLP | 1,313,433 | $435,062,000 | 1.99% |
| AtonRa Partners | 8,545 | $2,830,000 | 1.54% |
| Jackson Square Partners, LLC | 460,133 | $152,414,000 | 1.51% |
| TrinityPoint Wealth, LLC | 22,352 | $7,404,000 | 1.34% |
| Winslow Capital Management, LLC | 904,536 | $299,619,000 | 1.30% |
| Sonen Capital LLC | 3,055 | $1,012,000 | 1.22% |
| COUNTRY TRUST BANK | 126,465 | $41,890,000 | 1.17% |
| 2Xideas AG | 43,877 | $14,534,000 | 1.02% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 129,135 | $42,775,000 | 1.01% |
| SCOUT INVESTMENTS, INC. | 185,591 | $61,475,000 | 0.98% |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 913,808 | $302,690,000 | 0.90% |
| Baillie Gifford | 3,709,250 | $1,228,651,000 | 0.86% |
About ABIOMED INC
Abiomed Inc. is a leading medical device company that specializes in developing and manufacturing advanced heart pumps. The company's flagship product, the Impella heart pump, is a minimally invasive device that provides temporary circulatory support to patients with severe heart failure.
Abiomed's innovative technology has revolutionized the treatment of heart disease, providing physicians with a safe and effective alternative to traditional open-heart surgery. The Impella heart pump is designed to be inserted through a small incision in the patient's leg and threaded up to the heart, where it can provide up to 5 liters of blood flow per minute.
The company's commitment to innovation and patient care has earned it numerous accolades, including recognition as one of the fastest-growing companies in the United States. Abiomed's success is due in large part to its talented team of engineers, scientists, and medical professionals, who work tirelessly to develop new and improved heart pumps that can save lives.
Abiomed's leadership team is also a key factor in the company's success. CEO Michael R. Minogue has been with the company since 2004 and has overseen its growth from a small startup to a global leader in the medical device industry. COO Thorsten Siess has also played a critical role in Abiomed's success, overseeing the company's manufacturing and supply chain operations.
Overall, Abiomed Inc. is a company that is dedicated to improving the lives of patients with heart disease. Its innovative technology and talented team of professionals have made it a leader in the medical device industry, and its commitment to patient care will continue to drive its success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists ABIOMED INC's shareholders in Q1 2022. To view ABIOMED INC's shareholder history, click here.